Apollomics News

Apollomics Announces ~$6M Private Placement Financing; Pursuant To The Terms Of The Subscription Agreements, Co Is Selling An Aggregate Of 19,166,666 Class A Ordinary Shares At A Price Of $0.30/Share

Apollomics Inc. (NASDAQ:APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced th

BenzingaMay 8 17:28 ET

Express News | Apollomics: Purchasers Agreed to Purchase Aggregate of 19.2 Mln Class a Shares, Par Value $0.0001 per Share, of Co at Price per Share of $0.30

ReutersMay 8 16:50 ET

Express News | Apollomics Inc: Pipe Subscription Agreements for a Private Placement With Certain Accredited Investors

ReutersMay 8 16:48 ET

Express News | Apollomics Announces Private Placement Financing and Addition to Board of Directors

ReutersMay 8 16:05 ET

Apollomics Price Target Cut to $2.00/Share From $5.00 by HC Wainwright & Co.

Apollomics Price Target Cut to $2.00/Share From $5.00 by HC Wainwright & Co.

Dow JonesMay 8 15:22 ET

HC Wainwright & Co. Maintains Buy on Apollomics, Lowers Price Target to $2

HC Wainwright & Co. analyst Robert Burns maintains Apollomics with a Buy and lowers the price target from $5 to $2.

Analyst UpgradesMay 8 15:12 ET

Maintaining Buy Rating on Apollomics Amid Clinical Setbacks and Pipeline Potential

TipRanksMay 8 06:27 ET

Express News | Apollomics, Inc. : H.c. Wainwright Cuts Target Price to $2 From $5

ReutersMay 8 06:15 ET

Express News | Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas With Met Fusion Gene

ReutersApr 25 08:30 ET

Express News | Apollomics Inc Files For Mixed Shelf Of Up To $200M

Moomoo 24/7Apr 1 16:34 ET

12 Health Care Stocks Moving In Monday's After-Market Session

GainersOpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. The market value of their outstanding shares is at $7.4 million. Galecto (NASDAQ:GLTO) shares in

BenzingaApr 1 16:31 ET

Apollomics Price Target Cut to $6.50/Share From $11.00 by EF Hutton

Apollomics Price Target Cut to $6.50/Share From $11.00 by EF Hutton

Dow JonesApr 1 08:48 ET

Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Apollomics (APLM) and Iterum Therapeutics (ITRM)

TipRanksApr 1 06:30 ET

Apollomics Is Maintained at Buy by HC Wainwright & Co.

Apollomics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesApr 1 06:28 ET

Express News | HC Wainwright & Co. Maintains Buy on Apollomics, Lowers Price Target to $5

Moomoo 24/7Apr 1 06:18 ET

Apollomics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 635.29% HC Wainwright & Co. $17 → $5 Maintains Buy 11/20/2023 2400% HC Wainwright & Co. → $17 R

BenzingaApr 1 06:16 ET

Earnings Call Summary | Apollomics(APLM.US) Q4 2023 Earnings Conference

The following is a summary of the Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript:Financial Performance:Apollomics ended 2023 with cash and equivalents of $37.8 million.The company managed to

moomoo AIMar 28 16:11 ET · Conference Call

Apollomics GAAP EPS of -$2.32

Seeking AlphaMar 28 08:42 ET

Express News | Apollomics Completed Patient Enrollment For The Uproleselan (Apl-106) Phase 3 Bridging Study In China – Topline Data Expected In The First Half Of 2025

Moomoo 24/7Mar 28 07:07 ET

Express News | Apollomics FY EPS $(2.32) Up From $(8.44) YoY

Moomoo 24/7Mar 28 07:06 ET